PDGFRB and cholangiocarcinoma: In our study, we examined the sensitivity of PDGFR inhibitors, specifically imatinib, sunitinib, and CP-673451, in OV-associated CCA cell lines—HuCCA-1, KKU-M055, and KKU-100.